TRX-0237 mesylate

TRx 0237 mesylate (LMTX, Hydromethylthionine) is a second-generation tau protein aggregation inhibitor. For the treatment of Alzheimer's disease and frontotemporal dementia.

TRX-0237 mesylate dose-dependently rescues learning impairment in L1 (a mouse strain overexpressing truncated tau protein) and restores its behavioral resilience in the water maze test (minimum dose administered: 9 mg MT/kg). In L66 (a mouse strain overexpressing full-length tau-P301S/G335D), it modulates its motor learning (effective dose: 4 mg MT/kg). It reduced the number of tau-active neurons, especially in the hippocampus and entorhinal cortex of L1, and more generally in the L66 strain.